Enfermedad pulmonar intersticial asociada a vasculitis sistémica ANCA positiva. Monografía 2018

Nicolás Martín Lloves Schenone

doi:10.47196/rar.v29i3.520

Nicolás Martín Lloves Schenone Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina

DOI: https://doi.org/10.47196/rar.v29i3.520

Palabras clave: enfermedad, pulmonar, vasculitis, sistémica

Resumen

Las vasculitis sistémicas son un grupo heterogéneo de enfermedades poco frecuentes que cursan con inflamación de los vasos sanguíneos y que pueden afectar potencialmente cualquier órgano y sistema del cuerpo. Generan deterioro u obstrucción al flujo sanguíneo y daño a la integridad de la pared vascular

Citas

I. Pagnoux C. Updates in ANCA-associated vasculitis. Eur J Rheumatol 2016; 3:122-33.

II. Benarous L, Terrier B, Laborde-Casterot H, et al. Employment, work disability and quality of life in patients with ANCA associated vasculitides. The EXPOVAS study. Clin Exp Rheumatol 2017; 35 (Suppl.103):S40-46.

III. Trieste L, Palla I, Baldini C, et al. Systemic vasculitis: how little we know about their societal and economic burden. Clin Exp Rheumatol 2012; 30 (Suppl. 73):S154-6.

IV. Barra LJ, Bateman EA, Rohekar S, Pagnoux C, Moradizadeh M: Assessment of work limitations and disability in systemic vasculitis. Clin Exp Rheumatol 2016; 34 (Suppl. 97):S111-4.

V. Talarico R, Baldini C, Della Rossa A et al. Large- and small-vessel vasculitis: a critical digest of the 2010-2011 literature. Clin Exp Rheumatol 2012; 30 (Suppl. 70):S130-8.

VI. Talarico R, Baldini C, Della Rossa A, Carli L, Tani C, Bombardieri S. Systemic vasculitis: a critical digest of the recent literature. Clin Exp Rheumatol 2013; 31(Suppl. 75):S84-8.

VII. Della Rossa A, Cioffi E, Elefante E, et al. Systemic vasculitis: an annual critical digest of the most recent literature. Clin Exp Rheumatol 2014; 32 (Suppl. 82):S98-105.

VIII. Stagnaro C, Cioffi E, Talarico R, Della Rossa A. Systemic vasculitides: a critical digest of the most recent literature. Clin Exp Rheumatol 2015; 33 (Suppl. 89):S-145-54.

IX. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1–11.

X. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318:1651–7.

XI. Nolle B. Anticytoplasmic autoantibodies: their inmunodiagnostic value in Wegener granulomatosis. Annals of Internal Medicine Vol III n 1 July 1989.

XII. Savige J, Pollock W, Trevisin M. What do antineutrophil cytoplasmic antibodies (ANCA) tell us? Best Pract Res Clin Rheumatol. 2005 Apr;19(2):263-76.

XIII. Kallenberg CG: Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol 2015; 33 (Suppl. 92):S11-4.

XIV. Foulon G, Delaval P, Valeyre D,Wallaert B, Debray MP, Brauner M, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med 2008;102:1392–8.

XV. Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE. Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 1990;65:847–56.

XVI. Hervier B, Pagnoux C, Agard C, Haroche J, Amoura Z, Guillevin L, et al. Vasculitis study, pulmonary fibrosis associated with ANCA-positive vasculitides. Retrospective study of 12 cases and review of the literature. Ann Rheum Dis 2009;68:404–7.

XVII. Nozu T, Kondo M, Suzuki K, Tamaoki J, Nagai A. A comparison of the clinical features of ANCA-positive and ANCA-negative idiopathic pulmonary fibrosis patients. Respiration 2009;77:407–15.

XVIII. Tzelepis GE, Kokosi M, Tzioufas A, Toya SP, Boki KA, Zormpala A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J 2010; 36:116–21.

XIX. Arulkumaran N, Periselneris N, Gaskin G, Strickland N, Ind PW, Pusey CD, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology (Oxford) 2011;50:2035–43.

XX. Flores-Suarez LF, Ruiz N, Saldarriaga Rivera LM, Pensado L. Reduced survival in microscopic polyangiitis patients with pulmonary fibrosis in a respiratory referral centre. Clin Rheumatol 2015;34:1653–4.

XXI. Nachman PH, Henderson AG. Pathogenesis of lung vasculitis. Semin Respir Crit Care Med 2011;32:245–53.

XXII. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992;116:488–98.

XXIII. Anderson G, Coles ET, Crane M, Douglas AC, Gibbs AR, Geddes DM, et al. Wegener’s granuloma. A series of 265 British cases seen between 1975 and 1985. A report by a sub-committee of the British Thoracic Society Research Committee. Q J Med 1992;83:427–38.

XXIV. Comarmond C, Cacoub P. Granulomatosis with polyangiitis (Wegener): clinical aspects and treatment. Autoimmun Rev 2014;13:1121–5.

XXV. Schirmer JH, Wright MN, Vonthein R, Herrmann K, Nolle B, Both M, et al. Clinical presentation and long-term outcome of 144 patients with microscopic polyangiitis in a monocentric German cohort. Rheumatology (Oxford) 2016;55:71–9.

XXVI. Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999;42:421–30.

XXVII. Villiger PM, Guillevin L. Microscopic polyangiitis: clinical presentation. Autoimmun Rev 2010;9:812–9.

XXVIII. Sada K, Yamamura M, Harigai M, Fujii T, Dobashi H, Takasaki Y, Ito S, Yamada H, Wada T, Hirahashi J, Arimura Y, Makino H; Research Committee on Intractable Vasculitides, the Ministry of Health, Labour and Welfare of Japan: Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 2014; 16:R101.

XXIX. Eschun GM, Mink SN, Sharma S. Pulmonary interstitial fibrosis as a presenting manifestation inn perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 2003;123:297–301.

XXX. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 2004;9:190–6.

XXXI. Kono M, Nakamura Y, Enomoto N, Hashimoto D, Fujisawa T, Inui N, et al. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 2014;9:e94775.

XXXII. Comarmond C, Crestani B, Tazi A, Hervier B, Adam-Marchand S, Nunes H, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014; 93:340–9.

XXXIII. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013;107:608–15.

XXXIV. Tzelepis GE, Kokosi M, Tzioufas A, et al. Prevalence and outcome of pulmonary fibrosis in microscopic polyangiitis. Eur Respir J. 2010;36:116–21

XXXV. Foulon G, Delaval P, Valeyre D, et al. ANCA-associated lung fibrosis: analysis of 17 patients. Respir Med. 2008;102:1392–8.

XXXVI. Kagiyama N, Takayanagi N, Kanauchi T, Ishiguro T, Yanagisawa T, Sugita Y. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res. 2015;2:e000058.

XXXVII. Ando M, Miyazaki E, Ishii T, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med. 2013;107:608– 15.

XXXVIII. Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature. Medicine (Baltimore) 2014;93:340–9.

XXXIX. Hosoda C, Baba T, Hagiwara E, Ito H, Matsuo N, Kitamura H, et al. Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis. Respirology 2016;21:920–6.

XL. Fernandez Casares M, Gonzalez A, Fielli M, Caputo F, Bottinelli Y, ZamboniM. Microscopic polyangiitis associated with pulmonary fibrosis. Clin Rheumatol 2015;34:1273–7.

XLI. Yamagata M, Ikeda K, Tsushima K, Iesato K, Abe M, Ito T, et al. Prevalence and responsiveness to treatment of lung abnormalities on chest computed tomography in patients with microscopic polyangiitis: a multicenter, longitudinal, retrospective study of one hundred fifty consecutive hospital-based Japanese patients. Arthritis Rheum 2016;68:713–23.

XLII. Ando Y, Okada F, Matsumoto S, Mori H. Thoracic manifestation of myeloperoxidase antineutrophil cytoplasmic antibody (MPO-ANCA)-related disease. CT findings in 51 patients. J Comput Assist Tomogr 2004;28:710–6.

XLIII. Travis WD, Costabel U, Hansell DM, King Jr TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013;188:733–48.

XLIV. Tanaka T, Otani K, Egashira R, Kashima Y, Taniguchi H, Kondoh Y, Kataoka K, Shiraki A, Kitasato Y, Leslie KO, Fukuoka J. Interstitial pneumonia associated with MPO-ANCA: clinicopathological features of nine patients. Respir Med. 2012 Dec;106(12):1765-70. doi: 10.1016/j. rmed.2012.08.024. Epub 2012 Sep 17.

XLV. Chino H, Hagiwara E, Kitamura H, Baba T, Yamakawa H, Takemura T, Ogura T. Myeloperoxidase Anti-Neutrophil Cytoplasmic Antibody-Positive Interstitial Pneumonia Associated with Granulomatosis with Polyangiitis Diagnosed by Surgical Lung Biopsy. Novel Insights from Clinical Practice. 2016, Vol.92, No. 5.

XLVI. Homma S, Matsushita H, Nakata K. Pulmonary fibrosis in myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitides. Respirology. 2004;9:190–6.

XLVII. Schnabel A, Reuter M, Csernok E, Richter C, Gross WL. Subclinical alveolar bleeding in pulmonary vasculitides: correlation with indices of disease activity. Eur Respir J 1999;14:118–24.

XLVIII. Guilpain P, Chereau C, Goulvestre C, Servettaz A, Montani D, Tamas N, et al. The oxidation induced by antimyeloperoxidase antibodies triggers fibrosis in microscopic polyangiitis. Eur Respir J 2011;37:1503–13.

XLIX. Yan Z, Kui Z, Ping Z. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis. Autoimmun Rev 2014;13:1020–5.

L. Mark EJ, Matsubara O, Tan-Liu NS, Fienberg R. The pulmonary biopsy in the early diagnosis of Wegener’s (pathergic) granulomatosis: a study based on 35 open lung biopsies. Hum Pathol 1988;19:1065–71.

LI. Holle JU, Gross WL. Treatment of ANCA-associated vasculitides (AAV). Autoimmun Rev 2013;12:483–6.

LII. Ando M, Miyazaki E, Ishii T, Mukai Y, Yamasue M, Fujisaki H, et al. Incidence of myeloperoxidase anti-neutrophil cytoplasmic antibody positivity and microscopic polyangitis in the course of idiopathic pulmonary fibrosis. Respir Med 2013;107:608–15.

LIII. Yates M, Watts RA, Bajema IM, Cid MC, Crestani B, Hauser T, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann Rheum Dis 2016;75:1583–94.

LIV. McGeoch L, Twilt M, Famorca L, Bakowsky V, Barra L, Benseler SM, et al. CanVasc recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitides. J Rheumatol 2016;43:97–120.

LV. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCAassociated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003;41:776– 84.

LVI. Hirayama K, Kobayashi M, Usui J, Arimura Y, Sugiyama H, Nitta K, et al. Pulmonary involvements of anti-neutrophil cytoplasmic autoantibody-associated renal vasculitis in Japan. Nephrol Dial Transplant 2015;30(Suppl. 1):i83–93.